Skip to content
Search AI Powered

Latest Stories

GSK's antibiotic drug to treat uncomplicated UTIs meets main goals

British pharmaceutical giant GSK said on Saturday (April 15) its oral antibiotic drug to treat uncomplicated urinary tract infections (uUTI) in female adults and adolescents met the main goals in late-stage trials.

The drug, gepotidacin, in phase III trials, met its primary goals of being on a par or better than nitrofurantoin, the current standard of care for the treatment of uUTIs, the company said.


GSK plans to submit results of the trials to the United States Food and Drug Administration for review later in the second quarter.

The drug, if approved, could become the first new type of antibiotic, which is critically important for countering drug-resistant infections, to treat uUTIs in 20 years, the company said.

"Gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI," Chris Corsico, senior vice president of development at GSK, said.

More than half of all women globally are affected by uUTIs in their lifetime, GSK said.

In 2021, GSK expected the drug could assume blockbuster status, meaning up to 1 billion pounds in non-risk adjusted peak year sales.

More For You

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Prakash Patel was speaking at a panel discussion at the Sigma Conference

Sigma Conference: "Pharmacists need greater role in integrated care boards," says CPE representative

Pharmacists need to be a part of integrated care boards (ICB) to stop GPs from monopolising services based on their needs rather than the needs of the patient, according to Prakash Patel, Community Pharmacy Engaland (CPE) representative for North London.

“The evolution of the NHS should mean there can be no decision of pharmacy without pharmacist,” Patel told delegates at the Sigma Pharmacy Conference in Baku, Azerbaijan on Tuesday.

Keep ReadingShow less
David Webb
David Webb, NHS England's Chief Pharmaceutical Officer
David Webb, NHS England's Chief Pharmaceutical Officer

Sigma Conference: "Community pharmacy ready to make a profound contribution to 10 Year Health Plan," says David Webb

A national community pharmacy prescribing service remains a long-term goal of the government, according to NHS chief pharmaceutical officer, David Webb.

The Labour Party in its election manifesto last year said it would “create a Community Pharmacist Prescribing Service, granting more pharmacists independent prescribing rights”.

Keep ReadingShow less
Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less